​

Pasithea Therapeutics Stock (NASDAQ:KTTA)

OwnershipFinancialsChart
Pasithea Therapeutics by TradingView

Previous Close

$0.84

52W Range

$0.28 - $2.06

50D Avg

$0.77

200D Avg

$0.81

Market Cap

$5.92M

Avg Vol (3M)

$411.30K

Beta

0.22

Div Yield

-

KTTA Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Sep 15, 2021

Website

KTTA Performance

KTTA Financial Summary

Dec 24Dec 23Dec 22
Revenue--$486.56K
Operating Income$-14.25B$-15.98M$-14.82M
Net Income$-13.90B$-15.96M$-13.06M
EBITDA$-14.25B$-15.33M$-12.58M
Basic EPS$-12.69K$-12.65$-10.34
Diluted EPS$-12.69K$-13.01$-10.34

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
VIVSVivoSim Labs, Inc.
KALAKALA BIO, Inc.
PLRZPolyrizon Ltd.
VYNEVYNE Therapeutics Inc.
QNRXQuoin Pharmaceuticals, Ltd.
TCRTAlaunos Therapeutics, Inc.
CYCNCyclerion Therapeutics, Inc.